FDAnews Device Daily Bulletin

House Committee Rebukes Mylan CEO, FDA Official on EpiPen Fee

Sept. 27, 2016

If Mylan wants to improve access to its emergency allergy treatment EpiPen, then the company should lower the price of the drug, instead of marketing a generic version, members of the House Committee on Oversight and Government Reform said.

Committee members grilled Mylan CEO Heather Bresch and CDER Deputy Director Doug Throckmorton on the company’s virtual monopoly of the epinephrine auto-injector market in a hearing that lasted more than two hours.

In less than a decade, the price of Mylan’s EpiPen rose to $608, up from about $100 in 2008. Bresch attributed this price to an increase in a cost of goods by about 100 percent. At $608, the company only makes $50 per EpiPen, Bresch said. — Josè Vasquez

View today's stories